Opinion|Videos|September 16, 2024
Challenges in Managing Co-Morbid CRM Conditions
Key Takeaways
- Polypharmacy and drug-drug interactions complicate the management of co-morbid CRM conditions, necessitating careful medication review and adjustment.
- Overlapping symptoms of CRM conditions require a multidisciplinary approach for accurate diagnosis and effective management.
A panel of medical experts examines the challenges in managing co-morbid cardiometabolic conditions, emphasizing the most prevalent complications associated with this disease state.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What are the major clinical challenges in managing patients with co-morbid CRM conditions?
This activity is supported by Boehringer Ingelheim Pharmaceuticals Inc. and Eli Lilly and Company who provided financial support for this program.
Advertisement
Related to this article
Phase 3 wins for ianalumab and dazodalibep bring targeted therapies closer for Sjögren disease as patients face diagnostic delays and high costs.
Although PMOS Awareness Month has ended, the conversation continues, with experts saying closing diagnostic and care gaps requires ongoing efforts.
Invivyd's VYD2311 shows superior safety and tolerability vs Comirnaty in the phase 3 LIBERTY trial, with no vaccine interference.
Survodutide achieved up to 13.1% weight loss vs 3.1% with placebo at 76 weeks in adults with obesity and T2D in the phase 3 SYNCHRONIZE-2 trial.
A rare case of soft-tissue sarcoma spreading to the heart shows how multimodal imaging guided diagnosis and care in a 36-year-old man.
Weekend catch-up sleep was associated with lower odds of overactive bladder and milder symptoms, with the benefit concentrated in the first 1.5 hours.
The triple agonist also lowered HbA1C by up to 1.6% over 80 weeks, with up to 40% of participants reaching normal levels.
A network meta-analysis found vibegron outperformed mirabegron and tolterodine on several OAB efficacy measures but had higher odds of adverse events.
Advertisement
Advertisement
Trending on AJMC
1
CMS Finalizes Mandatory GLOBE Model to Test Lower Part B Drug Costs
2
Dual Agonist Survodutide Delivers Up to 13.1% Weight Loss in T2D
3
Lung Cancer Screening Lags for People With HIV as Eligibility Triples
4
VYD2311 Shows Superior Safety vs mRNA COVID-19 Vaccine
5